Onkologisches Zentrum Donauwörth
- Address
- lock Available on a paid plan
Onkologisches Zentrum Donauwörth
Onkologisches Zentrum Donauwörth is a specialized oncology center dedicated to advancing cancer treatment through innovative clinical research. The center demonstrates expertise in both hematologic malignancies and solid tumor oncology, with a particular focus on precision medicine approaches and patient-centered care strategies.
- Myeloproliferative neoplasms, specifically polycythemia vera with artificial intelligence-driven predictive modeling for treatment resistance
- Hormone receptor positive HER2 negative breast cancer utilizing combination targeted therapy and endocrine treatment
- Digital health integration for comprehensive side effect management and patient monitoring
The center's research portfolio reflects a commitment to personalized oncology care, incorporating cutting-edge technologies such as machine learning algorithms to predict hydroxyurea resistance in polycythemia vera patients. In breast cancer research, the center evaluates innovative combinations of CDK4/6 inhibitors with endocrine therapy, while simultaneously implementing digital solutions to enhance patient quality of life and treatment adherence through real-time symptom management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Onkologisches Zentrum Donauwörth
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| HU-F-AIM - A prospective, interventional study to evaluate HU-resistance in polycythemia vera patients who meet predictive parameters identified in the machine learning project PV-AIM | Novartis Pharma GmbH | Phase III | Not Recruiting | Jul 2023 | Feb 2026 |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abemaciclib | 1 | Unknown | 2022-04-26 | 2022-04-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.